Biotron Limited (BITRF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 5.15 Million AUD | 3.12% |
| 2023 | 4.99 Million AUD | 15.16% |
| 2022 | 4.33 Million AUD | -7.04% |
| 2021 | 4.66 Million AUD | 5.02% |
| 2020 | 4.44 Million AUD | 60.19% |
| 2019 | 2.77 Million AUD | -14.2% |
| 2018 | 3.23 Million AUD | -32.4% |
| 2017 | 4.78 Million AUD | 3.32% |
| 2016 | 4.62 Million AUD | 4.18% |
| 2015 | 4.44 Million AUD | -8.92% |
| 2014 | 4.87 Million AUD | -1.54% |
| 2013 | 4.95 Million AUD | 60.16% |
| 2012 | 3.09 Million AUD | 27.76% |
| 2011 | 2.42 Million AUD | 26.42% |
| 2010 | 1.91 Million AUD | 4.09% |
| 2009 | 1.84 Million AUD | -22.97% |
| 2008 | 2.38 Million AUD | -37.02% |
| 2007 | 3.79 Million AUD | 22.58% |
| 2006 | 3.09 Million AUD | 17.29% |
| 2005 | 2.63 Million AUD | -24.91% |
| 2004 | 3.51 Million AUD | 32.36% |
| 2003 | 2.65 Million AUD | 39.82% |
| 2002 | 1.89 Million AUD | 22.76% |
| 2001 | 1.54 Million AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 1.06 Million AUD | -63.78% |
| 2024 Q4 | 1.06 Million AUD | 0.0% |
| 2024 FY | 5.11 Million AUD | 2.31% |
| 2024 Q1 | 1.5 Million AUD | -45.52% |
| 2024 Q2 | 2.94 Million AUD | 95.26% |
| 2023 FY | 4.99 Million AUD | 15.16% |
| 2023 Q2 | 2.14 Million AUD | 90.9% |
| 2023 Q1 | 1.12 Million AUD | 37.37% |
| 2023 Q3 | 1.39 Million AUD | -35.03% |
| 2023 Q4 | 2.76 Million AUD | 98.51% |
| 2022 Q4 | 818.81 Thousand AUD | -31.76% |
| 2022 Q3 | 1.19 Million AUD | -35.92% |
| 2022 FY | 4.33 Million AUD | -7.04% |
| 2022 Q1 | 968.96 Thousand AUD | -55.68% |
| 2022 Q2 | 1.87 Million AUD | 93.25% |
| 2021 Q3 | 1.1 Million AUD | -54.06% |
| 2021 Q1 | 1.22 Million AUD | -46.79% |
| 2021 Q4 | 2.18 Million AUD | 97.86% |
| 2021 FY | 4.66 Million AUD | 5.02% |
| 2021 Q2 | 2.4 Million AUD | 95.84% |
| 2020 Q2 | 2.04 Million AUD | 94.06% |
| 2020 Q4 | 2.3 Million AUD | 98.02% |
| 2020 FY | 4.44 Million AUD | 60.19% |
| 2020 Q1 | 1.05 Million AUD | -25.46% |
| 2020 Q3 | 1.16 Million AUD | -43.13% |
| 2019 FY | 2.77 Million AUD | -14.2% |
| 2019 Q4 | 1.41 Million AUD | 99.35% |
| 2019 Q3 | 710.71 Thousand AUD | 5.11% |
| 2019 Q2 | 676.16 Thousand AUD | -0.0% |
| 2019 Q1 | 676.16 Thousand AUD | -6.21% |
| 2018 Q1 | 895.48 Thousand AUD | -34.96% |
| 2018 FY | 3.23 Million AUD | -32.4% |
| 2018 Q4 | 720.92 Thousand AUD | 0.0% |
| 2018 Q3 | 720.92 Thousand AUD | -19.49% |
| 2018 Q2 | 895.48 Thousand AUD | -0.0% |
| 2017 FY | 4.78 Million AUD | 3.32% |
| 2017 Q4 | 1.37 Million AUD | 0.0% |
| 2017 Q3 | 1.37 Million AUD | 35.72% |
| 2017 Q1 | 1.01 Million AUD | 11.9% |
| 2017 Q2 | 1.01 Million AUD | 0.0% |
| 2016 Q4 | 906.58 Thousand AUD | 0.0% |
| 2016 Q2 | 1.4 Million AUD | 0.0% |
| 2016 Q1 | 1.4 Million AUD | 25.64% |
| 2016 FY | 4.62 Million AUD | 4.18% |
| 2016 Q3 | 906.58 Thousand AUD | -35.6% |
| 2015 Q4 | 1.12 Million AUD | 0.0% |
| 2015 Q3 | 1.12 Million AUD | 1.77% |
| 2015 FY | 4.44 Million AUD | -8.92% |
| 2015 Q2 | 1.1 Million AUD | -0.0% |
| 2015 Q1 | 1.1 Million AUD | -0.93% |
| 2014 FY | 4.87 Million AUD | -1.54% |
| 2014 Q3 | 1.11 Million AUD | -16.29% |
| 2014 Q2 | 1.32 Million AUD | 0.0% |
| 2014 Q1 | 1.32 Million AUD | 6.36% |
| 2014 Q4 | 1.11 Million AUD | 0.0% |
| 2013 FY | 4.95 Million AUD | 60.16% |
| 2013 Q3 | 1.24 Million AUD | 0.0% |
| 2013 Q4 | 1.24 Million AUD | 0.0% |
| 2012 FY | 3.09 Million AUD | 27.76% |
| 2011 FY | 2.42 Million AUD | 26.42% |
| 2010 FY | 1.91 Million AUD | 4.09% |
| 2009 FY | 1.84 Million AUD | -22.97% |
| 2008 FY | 2.38 Million AUD | -37.02% |
| 2007 FY | 3.79 Million AUD | 22.58% |
| 2006 FY | 3.09 Million AUD | 17.29% |
| 2005 FY | 2.63 Million AUD | -24.91% |
| 2004 FY | 3.51 Million AUD | 32.36% |
| 2003 FY | 2.65 Million AUD | 39.82% |
| 2002 FY | 1.89 Million AUD | 22.76% |
| 2001 FY | 1.54 Million AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -248.346% |
| CSL Limited | 3.44 Billion USD | 99.851% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 94.064% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -4.743% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1868.156% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 82.57% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 86.173% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -242.978% |
| Mesoblast Limited | 5.9 Million USD | 12.722% |
| Marizyme, Inc. | 19.23 Million USD | 73.226% |
| Genus plc | 147.7 Million USD | 96.512% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 41.325% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -283.973% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 38.228% |
| ContraFect Corporation | 56.88 Million USD | 90.945% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -16.842% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 37.7 Million USD | 86.34% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -84.606% |
| MultiCell Technologies, Inc. | 567.42 USD | -907724.363% |
| Accustem Sciences Inc. | 3.74 Million USD | -37.496% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 94.006% |
| EV Biologics, Inc. | 531.96 Thousand USD | -868.336% |
| Q BioMed Inc. | 3.43 Million USD | -49.89% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 79.158% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -96.047% |
| Biomind Labs Inc. | 994.18 Thousand USD | -418.132% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 23.323% |
| Skye Bioscience, Inc. | 13.54 Million USD | 61.977% |
| SQZ Biotechnologies Company | 85.61 Million USD | 93.984% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 20704.708% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -2.164% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -76.638% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 67.826% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -1222.286% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 97.716% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -151.436% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -180.704% |
| GB Sciences, Inc. | 1.42 Million USD | -262.629% |
| Alpha Cognition Inc. | 9.7 Million USD | 46.926% |
| argenx SE | 1.53 Billion USD | 99.664% |
| HST Global, Inc. | 140.9 Thousand USD | -3555.728% |
| Halberd Corporation | 74.84 Thousand USD | -6782.736% |
| Enzolytics Inc. | 2.17 Million USD | -136.346% |
| Resverlogix Corp. | 12.71 Million USD | 59.478% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -41.101% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 91.032% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 94.814% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -393.408% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -192.734% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -114.192% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -176.296% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -226.157% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -51.284% |
| AVAX Technologies, Inc. | 7.31 Million USD | 29.535% |
| ONE Bio Corp. | 6.44 Million USD | 20.061% |
| Zenith Capital Corp. | 8.94 Million USD | 42.4% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.376% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -29468.779% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -109.797% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -2903.444% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -168.164% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -357.919% |
| Agentix Corp. | 1.37 Million USD | -275.517% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 2.41 Million USD | -113.732% |
| Helix BioMedix, Inc. | 1.97 Million USD | -161.211% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 52.598% |
| BioStem Technologies, Inc. | 22.97 Million USD | 77.579% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -2738.349% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -285.731% |
| LadRx Corporation | 3.81 Million USD | -35.138% |
| Cell Source, Inc. | 4.32 Million USD | -19.093% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1139.816% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -457.782% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -457.782% |
| NovAccess Global Inc. | 2.46 Million USD | -108.824% |
| Affymax, Inc. | 39.38 Million USD | 86.921% |
| Itoco Inc. | 919.14 Thousand USD | -460.433% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -21.535% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -360.338% |
| CytoDyn Inc. | 18.05 Million USD | 71.474% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -20366.355% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -2240.614% |
| Qrons Inc. | 643.67 Thousand USD | -700.274% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -262.812% |
| SYBLEU INC | 160.87 Thousand USD | -3101.955% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -131.007% |
| Rebus Holdings, Inc. | 664 Thousand USD | -675.78% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -183.605% |
| Mobile Lads Corp. | 554.54 Thousand USD | -828.9% |
| International Stem Cell Corporation | 5.27 Million USD | 2.273% |
| Bioxytran, Inc. | 3.82 Million USD | -34.842% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -9685.299% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -25221.619% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 85.796% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -218.367% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -600.045% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -65.579% |
| Neutra Corp. | 243.82 Thousand USD | -2012.688% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 70.492% |
| PureTech Health plc | 144.59 Million USD | 96.438% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 74.86% |
| IXICO plc | 4.7 Million USD | -9.437% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 41.444% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 95.625% |
| CSL Limited | 3.89 Billion USD | 99.868% |
| Cellectis S.A. | 97.32 Million USD | 94.707% |